Open Government Portal
Found 10 records similar to Applications for medical devices under the Interim Order for use in relation to COVID-19 - Guidance document
The purpose of this document is to provide guidance to manufacturers of serological assays intended for the detection of antibodies to SARS-CoV-2, the virus that causes COVID-19 disease. The guidance outlines recommendations regarding the minimum testing that should be performed for SARS-CoV-2 diagnostics.
This document provides guidance to health authorities working to protect people in Canada from extreme heat by considering COVID-19 in heat alert and response planning. COVID-19 information evolves rapidly and this document is based on the medical community's current understanding of this issue.
This guidance has been adapted for Canadian use from the WHO document entitled "Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected – Interim guidance - 13 March 2020". This guidance is informed by currently available scientific evidence and expert opinion, and is subject to change as new information becomes available.
In order to develop technical guidance to support F/P/T public health authorities and front-line clinicians in health care settings responding to the novel coronavirus causing COVID-19, a number of assumptions were taken to develop interim guidance documents.
Support for workers, considerations for businesses navigating COVID-19 disruptions, Economic Response Plan, guidance for federal employees.
The first version of the National laboratory testing indication guidance for COVID-19 document was developed at the beginning of the COVID-19 outbreak. The original guidance document was finalized and approved by the Special Advisory Committee on April 16, 2020. Since then, significant developments in four areas have prompted the need to review and update the guidance. This document was updated in May 2020 to reflect these developments.
This document also discusses an approach to managing COVID-19 vaccines that are administered in a manner that differs from the recommendations of the manufacturer as authorized by Health Canada and/or the recommendations for use by National Advisory Committee on Immunization (NACI). These are referred to as vaccine administration errors or deviations. This document provides guidance only. Note that provincial and territorial protocols may differ from this guidance document.
Canada's response to the novel coronavirus (COVID-19) pandemic has been steadfast—keeping up with new scientific evidence and discoveries which allows us to adapt public health measures to prevent the spread of COVID-19, and providing guidance to health care workers so they have the appropriate tools they need to treat patients. Yet, there is still more to learn about COVID-19.
This guidance document supports Interim Order No. 2 Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19 (Interim Order No. 2).
The following guidance is directed to administrators of schools from kindergarten to grade 12 (K-12) and local public health authorities (PHAs) in jurisdictions where these schools exist. The guidance is not prescriptive in nature, rather, it supports administrators and PHA's to consider potential risks and mitigation strategies associated with the resumption of in-school classes during the COVID-19 pandemic.